Uros Markovic, MD, University of Catania, Catania, Italy, discusses the importance of regular serum free light chain (sFLC) assessment for the detection of early oligosecretory/free light chain escape in myeloma patients, regardless of disease secretory status. The retrospective study analysed real-world data from 130 relapsed/refractory myeloma patients treated with at least three prior lines of therapy between 2000 and 2020. Out of 106 patients who were normosecretory at diagnosis, 18 had oligosecretory/micromolecular escape at first disease relapse and a further six patients had oligosecretory/micromolecular escape at second disease relapse. This demonstrates the need for regular sFLC monitoring in multiple myeloma patients, regardless of secretory status. This interview took place during the 2021 European Myeloma Network (EMN) congress.